SCHEMBL17960019

SCHEMBL17960019

O=S(=O)(c1cc(Cl)c(O)c2ncccc12)C1CCCCC1

nearest known ligand 0.98

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ COMT P21964 9/20 0.98
▸ KDM4E B2RXH2 5/20 0.52
▸ MEN1 O00255 5/20 0.52
▸ KMT2A Q03164 5/20 0.52
▸ HSP90AA1 P07900 4/20 0.52
▸ MAPT P10636 4/20 0.52
▸ HTT P42858 4/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.52
▸ TDP1 Q9NUW8 4/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ OPRK1 P41145 3/20 0.52
▸ MMP14 P50281 3/20 0.52
▸ LMNA P02545 3/20 0.52
▸ TP53 P04637 2/20 0.52
▸ CYP3A4 P08684 2/20 0.52
▸ ALOX15 P16050 2/20 0.52
▸ ALOX12 P18054 2/20 0.52
▸ SLC6A2 P23975 2/20 0.52
▸ ALOX15B O15296 1/20 0.52
▸ NR1I2 O75469 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17960046 0.99 COMT (1.00) COMTKDM4EMEN1KMT2AHSP90AA1
SCHEMBL17960004 0.84 COMT (1.00) COMTKDM4EMEN1KMT2AMAPT
SCHEMBL17962306 0.81 COMT (0.73) COMTKDM4ECHEK1NTRK1FYN
SCHEMBL17962304 0.80 COMT (0.97) COMTKDM4EL3MBTL1
SCHEMBL22802119 0.79 COMT (0.67) COMTKDM4EMEN1KMT2AHSP90AA1
SCHEMBL17962272 0.78 COMT (1.00) COMTKDM4EL3MBTL1
SCHEMBL17960038 0.78 COMT (1.00) COMTKDM4EMEN1KMT2AHSP90AA1
SCHEMBL17960023 0.77 COMT (0.63) COMTKDM4EMEN1KMT2AMAPT
SCHEMBL17960036 0.76 COMT (0.73) COMTKDM4EMEN1KMT2AHSP90AA1
SCHEMBL17962378 0.75 COMT (0.69) COMTKDM4EMEN1KMT2AHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951057-B2 COMT inhibiting methods and compositions LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) 2018-04-24 — — US claimed
US-20160222001-A1 COMT Inhibiting Methods and Compositions LIEBER INSTITUTE, INC. 2016-08-04 — — US claimed
WO-2016123577-A1 COMT INHIBITING METHODS AND COMPOSITIONS LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) 2016-08-04 — — WO claimed
US-9951057-B2 COMT inhibiting methods and compositions LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) 2018-04-24 — — US disclosed
US-20160222001-A1 COMT Inhibiting Methods and Compositions LIEBER INSTITUTE, INC. 2016-08-04 — — US disclosed
WO-2016123577-A1 COMT INHIBITING METHODS AND COMPOSITIONS LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) 2016-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222001-A1 COMT Inhibiting Methods and Compositions COMT, SLC6A3, MAOA COMT 1/4885KDM4E 1957/4885MEN1 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback